Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure

Corbalán, Ramón; Acevedo, Mónica; Godoy, Iván; Jalil, Jorge; Campusano, Claudia; Klassen, J.

doi:10.1016/s1071-9164(98)90251-2

Cited by 33 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When stratified according to EF, the highest IGF1 values were found in patients with an EF 30-40%. Corbalan et al (26), in a small, uncontrolled study on nine patients with HF NYHA Class III, reported that treatment with enalapril restored low IGF1 values and improved cardiac function. Andreassen et al (27) reported increased IGF1 levels in patients treated with ACE inhibitors/ angiotensin II receptor blockers.…”

Section: Discussionmentioning

confidence: 99%

Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors

Chisalita¹,

Dahlström²,

Arnqvist³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: There are conflicting results regarding the association of circulating IGF1 with cardiovascular (CV) morbidity and mortality. We assessed the relationship between IGF1 levels and heart failure (HF), ischemic heart disease (IHD), and CV mortality in an elderly population taking into account the possible impact of angiotensin converting enzyme (ACE) inhibitors. Design and methods: A total of 851 persons aged 66-81 years, in a rural Swedish municipality, were subjected to medical history, clinical examination, electrocardiography, echocardiography, and fasting plasma samples. They were then followed for 8 years. Results and conclusion: Patients on ACE inhibitors had higher IGF1 levels compared with those without ACE inhibitors. In patients on ACE inhibitors, higher IGF1 values were found in patients with an ejection fraction (EF) !40% compared with EF R40%, in patients with higher proBNP levels in quartile 4 vs 1, and in patients with IHD when compared to those without ACE inhibitors (P!0.001). In patients without ACE inhibitors, no relationship was found between IGF1 levels and HF or IHD. In multivariate regression, only ACE inhibitors, ECG changes characteristic for IHD, and gender had a significant impact on IGF1. Patients with higher IGF1 levels in quintiles 4 and 5 compared to quintiles 1 and 2 had a 50% higher risk for CV death (PZ0.03). This was significant after adjustment for wellknown CV risk factors and ACE inhibitors (PZ0.03). Conclusions: Our results show that treatment with ACE inhibitors in an elderly population is associated with increased IGF1 levels, especially in patients with impaired cardiac function or IHD. High IGF1 levels tend to be associated with an increased risk for CV mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors

Chisalita¹,

Dahlström²,

Arnqvist³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition, myocardial IGF-1R expression was up-regulated by ACEIs, thus improving post-MI LV remodelling [176,182,183]. Moreover, the reduction in IGF-1 levels measured in HF patients was normalized by chronic enalapril therapy, with a parallel significant increase in ejection fraction and peak maximal oxygen consumption [184].…”

Section: Ischaemia and Cardiovascular Disease: Role Of Igf-1 Between mentioning

confidence: 98%

“…However, both prospective and cross-sectional studies have consistently shown associations between reduced IGF-1 levels and the metabolic syndrome [87,244], diabetes mellitus [22,87,245], LV dysfunction [184], and the presence and number of silent and symptomatic unstable carotid atherosclerotic plaques [62,146,156,246,247]. Moreover, cross-sectional studies have shown that reduced IGF-1 levels are present in patients with documented reduced coronary flow reserve [248], in patients with angina and normal coronary arteries [249] and IHD [250], as well as in patients in the acute phase of MI [251], or with worse post-acute MI outcome [50,252].…”

Section: Ischaemia and Cardiovascular Disease: Role Of Igf-1 Between mentioning

confidence: 99%

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

et al. 2011

View full text Add to dashboard Cite

IGF-1 (insulin-like growth factor-1) plays a unique role in the cell protection of multiple systems, where its fine-tuned signal transduction helps to preserve tissues from hypoxia, ischaemia and oxidative stress, thus mediating functional homoeostatic adjustments. In contrast, its deprivation results in apoptosis and dysfunction. Many prospective epidemiological surveys have associated low IGF-1 levels with late mortality, MI (myocardial infarction), HF (heart failure) and diabetes. Interventional studies suggest that IGF-1 has anti-atherogenic actions, owing to its multifaceted impact on cardiovascular risk factors and diseases. The metabolic ability of IGF-1 in coupling vasodilation with improved function plays a key role in these actions. The endothelial-protective, anti-platelet and anti-thrombotic activities of IGF-1 exert critical effects in preventing both vascular damage and mechanisms that lead to unstable coronary plaques and syndromes. The pro-survival and anti-inflammatory short-term properties of IGF-1 appear to reduce infarct size and improve LV (left ventricular) remodelling after MI. An immune-modulatory ability, which is able to suppress 'friendly fire' and autoreactivity, is a proposed important additional mechanism explaining the anti-thrombotic and anti-remodelling activities of IGF-1. The concern of cancer risk raised by long-term therapy with IGF-1, however, deserves further study. In the present review, we discuss the large body of published evidence and review data on rhIGF-1 (recombinant human IGF-1) administration in cardiovascular disease and diabetes, with a focus on dosage and safety issues. Perhaps the time has come for the regenerative properties of IGF-1 to be assessed as a new pharmacological tool in cardiovascular medicine.

show abstract

“…[12][13][14] To our knowledge, there have not been any studies investigating whether the concentrations of circulating IGF-1 and IGFBPs are related to the clinical condition of HCM, so we examined whether they are related to HCM, particularly CHF associated with HCM.…”

mentioning

confidence: 99%

Circulating Levels of Insulin-Like Growth Factor-1 and Its Binding Proteins in Patients With Hypertrophic Cardiomyopathy.

Saya

Hamada

Hiwada

2002

Circ J

View full text Add to dashboard Cite

Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure

Cited by 33 publications

References 26 publications

Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors

Increased IGF1 levels in relation to heart failure and cardiovascular mortality in an elderly population: impact of ACE inhibitors

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

Circulating Levels of Insulin-Like Growth Factor-1 and Its Binding Proteins in Patients With Hypertrophic Cardiomyopathy.

Contact Info

Product

Resources

About